Treatment Options in ErbB2 (HER2)-Overexpressing Breast Cancer
نویسندگان
چکیده
منابع مشابه
Treatment of HER2-overexpressing breast cancer.
The HER family of receptors consists of four closely related type 1 transmembrane TK receptors: HER1 (EGFR), HER2, HER3 and HER4. Signalling via the HER family of receptors underpins the majority of the intricate array of cellular activities on which cell survival and functionality depend. Aberrant HER2 expression and/or functionality have been implicated in the evolution of breast cancer and t...
متن کاملGeneration of CHO Stable Cell Line Overexpressing HER2: an In Vitro Model for Breast Cancer
Background: Breast cancer is the most common female malignancy and the leading cause of cancer mortality in women worldwide. The human epidermal growth factor receptor2 (HER2) is a transmembrane tyrosine kinase receptor that is usually overexpressed in human breast cancers. Stable cell lines heterogeneously overexpressing HER2 are highly required as in vitro models for breast cancer research. T...
متن کاملCurrent neoadjuvant treatment options for HER2-positive breast cancer
Approximately one quarter of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, the expression of which is associated with a relatively poor prognosis independent of other clinical and pathologic variables. Trastuzumab, a humanized recombinant monoclonal antibody specifically directed against the HER2 receptor, has been shown to be biologic...
متن کاملMolecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
The epidermal growth factor receptor 2 (HER2) is a tyrosine kinase overexpressed in nearly 20% to 25% of invasive breast cancers. Trastuzumab is a humanized monoclonal antibody that targets HER2. The majority of patients with metastatic breast cancer initially respond to trastuzumab, however, within 1 year of treatment disease progresses. Several molecular mechanisms have been described as cont...
متن کاملActivity of fulvestrant in HER2-overexpressing advanced breast cancer.
BACKGROUND Human epidermal growth factor receptor 2 (HER2) overexpression increases the aggressiveness of breast cancer cells resulting in poorer prognosis. Patients with HER2-positive disease are less responsive to endocrine therapies. Trastuzumab monotherapy results in objective responses in only approximately 15% of patients. Fulvestrant retains activity in cells overexpressing HER2 that are...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Breast Care
سال: 2008
ISSN: 1661-3805,1661-3791
DOI: 10.1159/000128287